Genmab A/S Q3 2026 EPS Tops Estimates at $0.56, but Revenue Misses at $1.19B

Genmab A/S (GMAB) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $1.19 billion, up 16% from a year earlier, below the $1.20 billion estimate, and adjusted EPS was $0.56, down 14% from a year earlier, above the $0.36 estimate.

Shares fell 0.1% in after-hours trading as of 4:20 p.m. ET, to $52.69 from a $52.74 close.

Q3 2026 scorecard

By our calculation, revenue was $11.0 million below the estimate and adjusted EPS was $0.20 above it. The QoQ column compares with the previous quarter's revenue of $1.16 billion and adjusted EPS of $0.54. The YoY column compares with $1.02 billion and $0.65 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 6 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 2 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $1.02 billion, $1.06 billion, $896.0 million, $1.16 billion and $1.19 billion.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.30 and revenue of $1.27 billion next quarter, based on 5 analysts.
• Next report. Genmab A/S is next expected to report on Feb. 16, 2027.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 16% increase to $1.19 billion.
• Related coverage. See our reports on Protagonist Therapeutics, Fidelity National Financial, Camden Property Trust and Callaway Golf.

Sources: Results are from Genmab A/S's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Genmab A/S's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.